Home » Market News » DirectorsTalk Highlights » Allergy Therapeutics Appoint new Non-Executive Director
Allergy therapeutics plc

Allergy Therapeutics Appoint new Non-Executive Director

Peter Jensen, Chairman of Allergy Therapeutics, commented: “We are pleased to welcome Scott to the Board. He brings extensive investor relations and marketing experience, particularly in the United States, which will be valuable to our Company as we continue to execute our global strategy. We also wish to take this opportunity to thank Jeff for his contribution and support to Allergy Therapeutics since February 2017.”

Allergy Therapeutics (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announced the appointment of Mr Scott Leinenweber to the Company’s Board as a Non-Executive Director, nominated by Abbott Laboratories, Inc. (NYSE: ABT) in replacement of Mr Jeff Barton who retires from the Board, both effective after close of business 7 November 2018.

Scott Leinenweber currently serves as Vice President of Investor Relations and Licensing & Acquisitions at Abbott. During his time in this role, he has been the lead spokesman with investors and served as lead for Abbott’s M&A activities in the Medical Devices, Diagnostics, Pharmaceuticals and Nutritionals business segments. Scott started his career at Abbott as a financial analyst in 1997, before moving into product management, sales and marketing roles across Abbott’s businesses. Mr Leinenweber holds a degree in finance from the University of Wisconsin-Oshkosh and a Masters of Business Administration from the Marquette University, Graduate School of Business.


Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.